Clean Intermittent Self-Catheterization (CISC) — Cost, Top Hospitals & Success Rates | MyMedicPlus

Clean intermittent self-catheterisation (CISC), also called clean intermittent catheterisation (CIC) or intermittent self-catheterisation (ISC), is a bladder management technique in which the patient inserts a catheter into their own urethra at regular intervals to drain urine from the bladder, then removes the catheter. Unlike indwelling urethral or suprapubic catheters, CISC mimics the natural cycle of bladder filling and emptying.

The technique was pioneered by Dr Jack Lapides at the University of Michigan in 1972. His landmark paper established that a clean (not sterile) technique was safe for chronic use because healthy, well-perfused bladder mucosa has natural resistance to infection from small numbers of bacteria introduced at catheterisation. This was a paradigm shift from the prevailing requirement for strict sterile technique, making CISC practical for unsupervised home use by patients themselves.

CISC is currently the gold standard long-term bladder management strategy for patients who cannot empty their bladder adequately by voiding. It is recommended by the European Association of Urology (EAU), British Association of Urological Surgeons (BAUS), and International Continence Society (ICS) for:

• Neurogenic lower urinary tract dysfunction (neurogenic bladder)
• Voiding dysfunction from non-neurological causes (bladder outlet obstruction, detrusor underactivity)
• Post-surgical urinary retention (after prostatectomy, rectal surgery, or urogynecological surgery)
• Chronic urinary retention of any aetiology where spontaneous voiding is insufficient

The key advantage of CISC over indwelling catheterisation is the preservation of physiological bladder cycling, which maintains bladder capacity, compliance, and wall elasticity, while dramatically reducing the risk of catheter-associated urinary tract infection (CAUTI), urethral erosion, and catheter-related complications seen with permanent indwelling catheters.

Patients require initial training from a specialist continence nurse or urologist, after which most can perform CISC independently and discreetly in any setting.

CISC is indicated across a broad range of conditions that impair bladder emptying. The common thread is inadequate or absent voluntary voiding, with resulting urinary retention, incomplete bladder emptying, or loss of voluntary bladder control.

Spinal Cord Injury (SCI)

Spinal cord injury at or above the sacral micturition centre (S2–S4) typically produces detrusor hyperreflexia (overactive neurogenic bladder) with or without detrusor-sphincter dyssynergia (DSD) — simultaneous detrusor contraction and external urethral sphincter contraction. This leads to incomplete emptying and dangerously high intravesical pressures that damage the upper urinary tracts (hydronephrosis, renal impairment). CISC, combined with anticholinergic medication (oxybutynin, solifenacin) or intradetrusor botulinum toxin A injections to suppress overactive detrusor contractions, is the primary management strategy for SCI bladders.

Multiple Sclerosis (MS)

Bladder dysfunction affects 50–90% of MS patients over time, including detrusor overactivity, incomplete emptying, and DSD. MS patients on CISC report significantly improved continence and reduced UTI frequency. Bladder dysfunction in MS often fluctuates with relapses, requiring flexible CISC schedules.

Spina Bifida and Congenital Neurological Anomalies

CISC is the cornerstone of bladder management in children and adults with spina bifida (myelomeningocele). Clean technique (not sterile) is used from infancy, often taught to parents initially and to the child themselves by school age. Early institution of CISC preserves renal function, which is the primary determinant of long-term outcomes in spina bifida. Urodynamic surveillance guides CISC frequency and anticholinergic use.

Diabetic Cystopathy (Autonomic Neuropathy)

Long-standing diabetes mellitus damages autonomic nerve supply to the detrusor, causing progressive detrusor underactivity and impaired bladder sensation. Patients develop large-volume, atonic bladders with overflow incontinence. CISC restores adequate bladder drainage and prevents upper tract deterioration.

Voiding Dysfunction After Prostatectomy

Temporary urinary retention or incomplete bladder emptying after radical prostatectomy (for prostate cancer) is common, particularly in the immediate post-operative period. CISC bridges the period until voiding recovers, allowing earlier catheter removal and reducing hospital stay.

Fowler's Syndrome

A condition occurring in young women characterised by sphincteric obstruction (paradoxical urethral sphincter contraction on attempted voiding) and urinary retention without neurological disease. CISC is the definitive management in most cases.

Post-Radiotherapy and Other Causes of Retention

Pelvic radiotherapy for cervical, rectal, or bladder cancer can cause detrusor hypocontractility and sphincter dysfunction. CISC is used when voiding is inadequate.

CISC is suitable for a wide range of patients, but requires pre-treatment assessment of bladder function, anatomy, and the patient's physical and cognitive capability to perform the procedure.

Urodynamic Assessment

Before commencing CISC, urodynamics (cystometrogram and voiding pressure-flow study) should be performed in patients with neurogenic bladder to assess:

• Bladder compliance — a low-compliance (stiff) bladder with high filling pressures (>40 cmH2O) causes upper tract damage and requires CISC combined with anticholinergic medication or botulinum toxin A before pressures are safe
• Bladder capacity — guides CISC frequency; target is to drain the bladder before it exceeds 400–500 mL
• Presence of DSD — detrusor-sphincter dyssynergia worsens emptying and increases pressure; CISC bypasses this obstruction
• Post-void residual (PVR) — PVR consistently >300 mL is associated with recurrent UTIs, overflow incontinence, and upper tract risk; CISC is indicated when PVR cannot be reduced to <150 mL by conservative measures

Patient Capability Assessment

Successful CISC requires:

• Adequate manual dexterity — ability to handle the catheter and guide it to the urethral meatus. Patients with significant hand weakness from cervical SCI, advanced MS, or severe rheumatoid arthritis may be unable to self-catheterise independently; adaptations (catheter holders, leg-bag connection, suprapubic port) are available, or a carer can perform the catheterisation
• Motivation and ability to maintain a schedule — CISC requires catheterisation 4–6 times daily; patients with significant cognitive impairment or poor adherence may need alternative management
• Adequate vision or, in women, willingness to learn anatomical self-location of the urethral meatus
• Appropriate urethral anatomy — urethral stricture, false passages, or significant BPH may require pre-treatment urethral dilatation or resection, or a Coudé tip catheter

Contraindications and Cautions

• Urethral trauma or complete urethral disruption
• Bladder neck or urethral surgery within 6 weeks (relative, discuss with surgeon)
• Known urethral stricture disease — treat stricture first, then reassess
• Patient refusal or inability to learn despite adequate training

Training Requirement

All patients starting CISC require structured teaching by a specialist nurse or continence advisor. Initial training takes 1–3 sessions and includes demonstration, supervised practice, catheter choice, problem-solving, and a written instruction sheet. Ongoing support via telephone or specialist continence clinic is essential in the first weeks.

The choice of catheter type is a clinically important decision that affects UTI rates, urethral trauma, patient comfort, and long-term adherence to CISC.

PVC (Polyvinyl Chloride) Catheters

Standard, low-cost catheters requiring lubrication with water-soluble gel (e.g. KY Jelly, Instillagel) before insertion. Available in multiple sizes (French/Ch sizing: most adults use Ch12–14 for females, Ch12–16 for males) and lengths (female 15–20 cm; male 40–45 cm). Can be reused for up to 7 days with cleaning (wash in soapy water, rinse, air dry, store in clean plastic bag) under the clean technique principle of Lapides. Single-use PVC catheters are also available. Cost-effective but less comfortable for some patients.

Hydrophilic-Coated Catheters

Catheters coated with a hydrophilic polymer that swells when activated with water to form a continuous, slippery surface. The coating drastically reduces urethral friction and trauma compared to unlubricated PVC. The NORDIC trial (LoFric catheter, 2007) demonstrated that hydrophilic catheters reduced symptomatic UTI incidence by 45% and reduced urethral trauma compared to uncoated PVC catheters. The EAU guidelines recommend hydrophilic catheters for all patients on long-term CISC where cost allows. The main disadvantage is cost — hydrophilic single-use catheters cost 3–5 times more per catheter than PVC.

Catheter Tip Designs

• Nelaton (straight) tip: Most commonly used. Suitable for straightforward urethral anatomy
• Tiemann/Coudé tip: Curved tip designed to navigate the prostatic urethra in men with BPH or urethral stricture. The curve is oriented anteriorly (upward) during insertion. Essential for men with significant prostatic enlargement
• Funnel-tipped catheters: Pre-lubricated closed system with collection bag; designed for patients who cannot hold a container. Used in wheelchair-dependent patients

Catheter Materials

• Standard PVC (polyvinyl chloride): Cost-effective, widely available, suitable for clean reuse technique
• Hydrophilic polymer-coated catheters (LoFric, SpeediCath, GentleCath): Single-use, pre-activated with water or saline sachet. Higher cost but superior tolerability and lower UTI rates for long-term users
• Latex: Avoid due to latex allergy risk, particularly in spina bifida patients who have high rates of latex sensitisation from repeated urological procedures

Catheterisation Frequency

CISC frequency is determined by individual bladder capacity and fluid intake. The general principle is to catheterise before the bladder volume exceeds 400–500 mL. For most patients, this means catheterising 4–6 times daily (approximately every 3–4 hours while awake). Fluid intake of 1,500–2,000 mL/day distributed evenly throughout the day helps predict catheterisation intervals. A bladder diary (recording fluid intake and catheterised volumes) is used to optimise frequency in the first weeks.

Male vs Female Technique

Male technique: Stand or sit. Clean hands and urethral meatus. Apply lubricant if using PVC catheter. Hold penis perpendicular to the body, retract foreskin if uncircumcised. Insert catheter gently (never force) while slowly advancing; slight resistance at the external urethral sphincter is normal — pause, breathe out, and advance slowly. Insert to the bifurcation of the catheter or until urine flows. Drain completely, then slowly withdraw.

Female technique: Sit on toilet. Clean hands and perineum. Women do not need a mirror to locate the urethra; they can use a finger to locate the urethral meatus by touch, just anterior to the vaginal opening. Insert the catheter 5–8 cm until urine flows. Drain completely and withdraw. Female catheters are shorter (15–20 cm). Shorter compact catheters (Speedicath Compact, LoFric Elle) are discreet and suitable for use in public facilities.

CISC offers compelling advantages over both indwelling catheterisation and untreated urinary retention, across multiple domains of health and quality of life.

Upper Urinary Tract Protection

The most important long-term benefit of CISC in neurogenic bladder is protection of the kidneys. Chronically elevated intravesical pressures (>40 cmH2O) cause vesicoureteral reflux, hydronephrosis, and progressive renal impairment. By regularly emptying the bladder, CISC prevents excessive bladder pressure accumulation and arrests the cycle of upper tract deterioration. In spina bifida patients, CISC instituted in infancy has transformed renal prognosis from progressive renal failure to preserved renal function into adulthood.

Lower UTI Rate Versus Indwelling Catheter

Catheter-associated UTI (CAUTI) is the most common healthcare-associated infection, primarily driven by indwelling urethral catheters. Indwelling catheters are associated with bacteriuria in essentially 100% of patients by 30 days. CISC dramatically reduces UTI risk compared to indwelling catheterisation. Hydrophilic CISC further reduces UTI rates by 45% compared to standard PVC (NORDIC trial). Patients on CISC experience clinically significant UTI (symptomatic, requiring antibiotics) at rates of 1–3 episodes per year — compared to monthly infection rates with indwelling catheters.

Preservation of Bladder Capacity and Compliance

CISC maintains the normal bladder filling-emptying cycle. Indwelling catheters cause the bladder to remain permanently drained, leading to bladder contracture (reduced capacity, fibrosis). CISC patients maintain better bladder compliance and capacity, enabling eventual return to spontaneous voiding in some conditions (e.g. post-prostatectomy retention, MS relapse-related retention).

Continence Improvement

In patients with overflow incontinence from incomplete emptying, CISC resolves the overflow by regularly draining the excessive post-void residual. When combined with anticholinergic medication or intradetrusor botulinum toxin A injections to suppress neurogenic detrusor overactivity, CISC enables continence in patients with SCI, MS, and spina bifida who would otherwise require incontinence pads or indwelling catheters.

Independence and Quality of Life

CISC gives patients control over their bladder function. Multiple quality-of-life studies using validated instruments (I-QOL, SF-36) demonstrate that patients on CISC report significantly better social functioning, emotional wellbeing, and independence compared to indwelling catheterisation. The ability to perform CISC discreetly in a public toilet without visible equipment is highly valued by patients. Adherence rates of 70–85% at one year are reported in engaged patient populations.

Reduced Urethral Erosion and Long-Term Complications

Indwelling urethral catheters cause urethral pressure necrosis, iatrogenic strictures, urethral erosion (particularly in men), and bladder stone formation from catheter encrustation. CISC eliminates these complications. The only urethral trauma associated with CISC is minor mucosal abrasion from insertion, substantially reduced with hydrophilic catheters.

CISC is generally very safe. Complications are typically mild and manageable. Understanding them allows patients to recognise problems early and seek appropriate guidance.

Urinary Tract Infection (UTI)

The most common complication. Most patients on CISC have bacteriuria (bacteria in the urine) without symptoms; this is called asymptomatic bacteriuria and does not require treatment. Antibiotic treatment should be reserved for symptomatic UTI with features such as fever, systemic upset, new or worsening autonomic dysreflexia (in SCI), suprapubic pain, or change in bladder spasms. Over-treatment of asymptomatic bacteriuria drives antimicrobial resistance. The STICS trial (BJUI 2018) demonstrated that antibiotic prophylaxis (trimethoprim 100 mg once daily at night) reduced symptomatic UTI incidence by 47% over 12 months in patients with neurogenic lower urinary tract dysfunction on CISC. However, given antibiotic resistance concerns, prophylaxis is reserved for patients with recurrent symptomatic UTIs (≥3 per year) on standard CISC.

Urethral Trauma and False Passage

Forceful catheter insertion against resistance, particularly with a straight catheter in men with an enlarged prostate, can cause urethral mucosal abrasion, submucous bleeding, or in severe cases, a false passage (perforation into the periurethral tissue). False passage typically presents as sudden loss of catheter advance resistance, failure to obtain urine, and periurethral bleeding. Management: stop CISC, seek urgent urological assessment, temporary suprapubic catheter insertion if urethral passage is compromised. Using a Coudé tip catheter in men with BPH and receiving instruction on gentle technique prevents most urethral trauma.

Urethral Stricture

Long-term CISC, particularly with non-hydrophilic catheters, can cause progressive urethral microtrauma leading to stricture formation. Using hydrophilic catheters, appropriate catheter sizing, and gentle technique significantly reduces this risk. Urethral stricture presents as increasing difficulty in passing the catheter; urethrography or flexible cystoscopy confirms the diagnosis. Treatment options include urethral dilatation, optical urethrotomy, or urethroplasty depending on stricture length and location.

Psychological Distress and Adherence Difficulties

Starting CISC can be daunting, particularly for patients who are newly disabled, embarrassed, or anxious about the procedure. Approximately 15–30% of patients have difficulty adhering to the recommended catheterisation schedule. Non-adherence (catheterising too infrequently) leads to bladder over-distension, high residuals, and UTI. Psychological support, peer mentoring (from experienced CISC users), and follow-up from specialist continence nurses are important in the first months.

Autonomic Dysreflexia (in High-Level SCI)

Patients with spinal cord injury at or above T6 can experience autonomic dysreflexia (AD) — a dangerous reflex hypertensive response triggered by any noxious stimulus below the level of injury, including bladder distension. Bladder overdistension from missed CISC episodes is the most common trigger of AD. Symptoms: sudden severe headache, flushing, sweating, and systolic blood pressure >150 mmHg. Management: sit the patient upright, identify and relieve the bladder trigger (immediate catheterisation), and if hypertension persists, administer sublingual nifedipine 10 mg or glyceryl trinitrate spray. AD is a medical emergency and underscores the importance of regular, timely CISC in high-level SCI patients.

Epididymo-Orchitis (in Men)

Retrograde bacterial infection from the urethra can occasionally reach the epididymis in men on CISC, causing epididymo-orchitis (pain, swelling of the testis). Treatment with a 2–4-week course of antibiotics (ciprofloxacin 500 mg twice daily for gram-negative organisms) is effective. Recurrent epididymo-orchitis may prompt consideration of bilateral vasectomy to prevent retrograde seeding.

Regular follow-up is essential to ensure CISC is achieving adequate bladder emptying, to monitor for complications, and to reassess the underlying condition as it evolves.

Initial Follow-Up (First 3 Months)

• 2–4 weeks after starting CISC: Review bladder diary (catheterised volumes, fluid intake, continent episodes, leak episodes). Confirm technique is correct. Assess catheterisation frequency — if volumes consistently >400 mL, increase frequency. Address problems (difficulty inserting catheter, discomfort, UTI symptoms)
• 3 months: Post-void residual measurement by bladder scan after attempted voiding. Check for UTIs since starting. Review catheter type — consider switching to hydrophilic if recurrent UTIs or discomfort on PVC catheter. Review anticholinergic medication effectiveness if prescribed

Ongoing Annual Review

• Renal function: Annual serum creatinine and eGFR, and renal/bladder ultrasound in neurogenic patients to screen for upper tract deterioration (hydronephrosis, renal scarring)
• Bladder capacity: Annual urodynamic assessment (cystometrogram) in neurogenic bladder patients to monitor compliance and capacity. Deteriorating compliance requires escalation of anticholinergic therapy or botulinum toxin A
• UTI frequency: Assess number of symptomatic UTIs per year; if ≥3, consider antibiotic prophylaxis, review technique, consider switching to hydrophilic catheters, check for bladder stones (cystoscopy or CT)
• Urethral integrity: In men on long-term CISC, if difficulty passing catheter develops, arrange urethrography or flexible cystoscopy to exclude stricture
• Bladder stones: Patients on long-term CISC are at increased risk of bladder calculi (from stagnant urine, foreign body reaction). Investigate with renal tract ultrasound if recurrent UTIs or haematuria

Antibiotic Prophylaxis Protocol

For patients with neurogenic bladder on CISC experiencing ≥3 symptomatic UTIs per year despite optimised technique and hydrophilic catheter use, STICS trial-based antibiotic prophylaxis is appropriate: trimethoprim 100 mg once daily at night (or co-trimoxazole 400/80 mg once daily if local resistance patterns suggest trimethoprim resistance). Review prophylaxis every 6 months and stop if UTI frequency has reduced. Urine culture before starting ensures the prophylactic agent covers the patient's colonising organisms.

Catheter Supply and Prescription

CISC catheters are available on prescription in the UK (Drug Tariff), Australia (NDIS), and many European countries. Prescription of 4–6 catheters per day for single-use hydrophilic catheters must be updated regularly. Patients should maintain a 1-month supply at home. Travel abroad with CISC supplies requires advance planning to ensure adequate catheter stock.

The cost of CISC is primarily driven by the catheter type selected and the frequency of catheterisation. For most patients with chronic conditions, CISC represents a long-term recurring cost.

Catheter Cost by Type

• Standard PVC catheters (single-use): USD 0.50–2 per catheter in bulk. At 5 catheterisations per day × 365 days = approximately USD 1,000–3,500 per year for single-use PVC. With reuse (up to 7 days), annual cost falls to USD 150–500
• Hydrophilic-coated single-use catheters (LoFric, SpeediCath, GentleCath): USD 3–8 per catheter. At 5 per day = USD 5,500–14,600 per year at retail prices in the USA. With NHS/insurance coverage (UK, Australia, Netherlands) cost to patient may be zero or a small co-payment
• Compact female catheters (SpeediCath Compact, LoFric Elle): Similar per-unit cost to standard hydrophilic but more portable; preferred by active female patients

Healthcare System Coverage

• United Kingdom (NHS): CISC catheters are prescribed on the NHS Drug Tariff. Hydrophilic single-use catheters are covered. No patient cost in England (free prescriptions for chronic conditions with medical exemption certificates); small charge in Wales/Scotland
• Australia: NDIS (National Disability Insurance Scheme) covers catheter supplies for eligible patients with neurogenic bladder. Medicare does not routinely cover catheter consumables
• USA: Medicare Part B covers intermittent catheters for patients with permanent urinary retention (up to 200 per month). Private insurance coverage varies; many plans cover medical necessity. The 21st Century Cures Act (2018) extended coverage for hydrophilic catheters
• India: PVC catheters are very low cost (INR 10–50/catheter); hydrophilic catheters are available but expensive without insurance. No national programme covers CISC supplies

Training Costs

Initial specialist nurse education for CISC typically requires 1–3 outpatient sessions. In the UK and Australia, this is provided through NHS/public continence services at no patient cost. In the USA, nurse education sessions cost USD 150–400 each if not covered by insurance. Online educational resources and manufacturer-provided demonstration kits reduce the need for multiple in-person sessions.

Indirect Cost Savings

CISC reduces the frequency of symptomatic UTI requiring antibiotic treatment, prevents hospitalisation for pyelonephritis and urosepsis, prevents renal failure requiring dialysis (in high-pressure neurogenic bladders), and eliminates the need for indwelling catheter changes (every 4–12 weeks by a district nurse in the UK). The long-term healthcare cost savings from preventing upper tract deterioration in spina bifida and SCI patients substantially exceed the cost of CISC supplies.

Medical Tourism Considerations

While CISC technique training can be initiated abroad at lower cost, the ongoing supply of catheters must be available in the patient's home country. Patients considering overseas treatment for neurogenic bladder should ensure their urologist in their home country is also managing their CISC programme, and that catheter supplies are readily accessible locally.

CISC is the preferred bladder management technique for most patients with incomplete bladder emptying, but alternatives exist for those who cannot perform CISC or for whom it is not appropriate.

Indwelling Urethral Catheter (IUC)

A Foley catheter left in the bladder continuously, draining to a leg bag or night bag. Simpler for the patient (no technique required), but associated with significantly higher UTI rates, urethral trauma, bladder stones, bladder contracture, and catheter-associated morbidity including urethral erosion in men. Appropriate for short-term use (post-operatively) or for patients who cannot perform CISC (severe disability, no carer support) and have no other option. IUC should be changed every 4–12 weeks by a healthcare provider.

Suprapubic Catheter (SPC)

An indwelling catheter inserted through the anterior abdominal wall into the bladder. Avoids urethral trauma; preferred over urethral catheterisation when long-term indwelling catheterisation is needed. Allows sexual activity with the catheter in situ. Can be changed independently at home by patients with good manual dexterity. SPC has similar infection rates to IUC but lower urethral complications. Insertion is a minor surgical procedure requiring cystoscopic guidance or ultrasound placement.

Assisted (Carer-Performed) Intermittent Catheterisation

For patients who cannot perform CISC independently (e.g. high cervical SCI with tetraplegia, severe MS with hand weakness), a trained carer (family member, community nurse) can perform intermittent catheterisation using the same clean technique. This preserves the advantages of intermittent catheterisation over indwelling catheterisation while accommodating the patient's physical limitations.

Mitrofanoff Appendicovesicostomy

A surgical procedure in which the appendix is used to create a continent, catheterisable channel from the bladder to the umbilicus or right iliac fossa. The patient self-catheterises through the Mitrofanoff stoma rather than the urethra. Particularly suitable for patients who cannot catheterise per urethra (women in wheelchairs with poor perineal access, urethral stricture, or urethral trauma). The stoma is continent between catheterisations (no leakage) due to the valve mechanism created at the bladder insertion point.

Bladder Augmentation (Clam Cystoplasty)

A surgical procedure that enlarges bladder capacity by incorporating a detubularised bowel segment (usually ileum) into the bladder. Used for small, low-compliance, high-pressure neurogenic bladders where CISC alone cannot maintain safe intravesical pressures. Post-augmentation, CISC is still required for bladder emptying (augmented bladders do not have normal contractile function). Complications include mucus production, bladder stones, and in the long term, a small risk of bladder tumours from the bowel mucosa.

Sacral Neuromodulation (InterStim)

Electrical stimulation of the S3 sacral nerve root via a surgically implanted electrode and generator modulates bladder activity. Effective for non-neurogenic overactive bladder and urinary retention (Fowler's syndrome). Not suitable for complete spinal cord injury but has a role in incomplete spinal cord injury and other selected neurological conditions.